Trial Profile
A phase III study of EBI-005 in subjects with moderate to severe ocular allergic conjunctivitis
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 30 Mar 2023
Price :
$35
*
At a glance
- Drugs Isunakinra (Primary)
- Indications Allergic conjunctivitis
- Focus Therapeutic Use
- 07 Mar 2023 According to a Carisma Therapeutics media release, Carisma Therapeutics merged with the Sesen Bio. The combined companies are named as Carisma Therapeutics.
- 16 May 2018 According to a Sesen Bio media release, Eleven Biotherapeutics changed its name to Sesen Bio.
- 19 Oct 2015 New trial record